Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthes Chooses Alternative-To-BMP Route In Bone Growth Factor Search

This article was originally published in The Gray Sheet

Executive Summary

Synthes-Stratec plans to forego immediate development of an orthobiologic bone growth factor, citing doubts about the product's feasibility in musculoskeletal repair applications
Advertisement

Related Content

Stryker OP-1 clarification
Stryker OP-1 clarification
OrthoLogic Chrysalin Phase III Fracture Repair NDA Study To Begin This Fall
Medtronic InFuse PMA Approval Sets Up CMS “New Technology” Add-On
Medtronic InFuse PMA Approval Sets Up CMS “New Technology” Add-On
Medtronic Expects FDA Orthopedics Panel Review For InFuse Bone Graft
Advertisement
UsernamePublicRestriction

Register

MT018134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel